Parkinson’s Disease - Pipeline Review, H1 2018 - ResearchAndMarkets.com

September 19, 2018

DUBLIN--(BUSINESS WIRE)--Sep 19, 2018--The “Parkinson’s Disease - Pipeline Review, H1 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Parkinson’s Disease - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Parkinson’s Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Parkinson’s Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Parkinson’s Disease and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 7, 44, 46, 3, 187, 56 and 11 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 46 and 12 molecules, respectively.

Parkinson’s Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Companies Featured

AbbVie Inc AC Immune SA AlfaSigma SpA Allergan Plc Bio-Modeling Systems SAS BioArctic AB BioElectron Technology Corp Biogen Inc Cardax Inc Denali Therapeutics Inc Diffusion Pharmaceuticals Inc Dizlin Medical Design AB Domain Therapeutics SA Easywell Biomedical Inc Eli Lilly and Co Genzyme Corp H. Lundbeck AS Hanmi Pharmaceuticals Co Ltd India Globalization Capital Inc InnoMedica Holding AG Intec Pharma Ltd IRLAB Therapeutics AB MimeTech Srl Mission Therapeutics Ltd Mitochon Pharmaceuticals Inc Montisera Ltd Pharnext SA Prana Biotechnology Ltd Priavoid GmbH ProMIS Neurosciences Inc Promius Pharma LLC Sanofi Serina Therapeutics Inc Xoc Pharmaceuticals Inc and many more...

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/777694/parkinsons?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180919005318/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Central Nervous System Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/19/2018 06:34 AM/DISC: 09/19/2018 06:33 AM


Update hourly